All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On 14 May 2019, Professor Hervé Tilly from the University of Rouen, Rouen, FR, and colleagues, published in The Lancet Oncology1 results from a phase Ib-II trial investigating the efficacy and safety of polatuzumab vedotin in combination with immnunochemotherapy in patients with naïve diffuse large B-cell lymphoma (DLBCL).
The current standard of care for DLBCL involves treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).2 However, in high-risk DLBCL patients, R-CHOP does not always lead to successful outcomes and the prognosis of patients not responding to R-CHOP is poor.2 The investigators of this trial assessed the tolerability and preliminary activity of polatuzumab vedotin together with cyclophosphamide, doxorubicin, prednisone (CHP) chemotherapy, as well as rituximab or obinutuzumab (anti-CD20 therapy), as first-line treatment for naïve DLBCL.
The primary objective of this ongoing, multicenter, open-label, non-randomized, phase Ib-II trial (NCT01992653) was treatment safety and tolerability, as well as the determination of the maximum tolerated dose of polatuzumab vedotin. Secondary endpoints included, overall response rate (ORR), complete response (CR), progression-free survival (PFS), event-free survival (EFS), and overall survival (OS).
|
Naïve DLBCL phase II cohort (n = 66) |
95% CI |
---|---|---|
ORR |
89% (n = 59) |
|
CR |
77% (n = 55 |
|
12-month PFS |
91% |
84–98 |
24-month PFS |
83% |
73–93 |
12-month OS |
94% |
88–100 |
12-month EFS |
80% |
71–90 |
Proportion of ongoing responses at 12 months |
95% |
89–100 |
The results of this phase Ib-II trial indicate that pola in combination with G-CHP or R-CHP has a manageable toxicity profile and leads to promising response outcomes in previously untreated patients with DLBCL
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox